← All trials
NCT06265051
Phase 2/Phase 3Interventional
Trials that are a combination of phases 2 and 3.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 9, 2024
- Primary completion
- Mar 1, 2027
- Completion date
- Sep 1, 2027
- First posted
- Feb 20, 2024
- Last posted
- May 28, 2024
- Enrollment
- 1360
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Huazhong University of Science and TechnologyLead sponsor
- Chengde Medical UniversityCollaborator
- Jingzhou Central HospitalCollaborator
- Huazhong University of Science and TechnologyOfficial
- Huazhong University of Science and TechnologyCollaborator
- Wuhan Central HospitalCollaborator
- Huazhong University of Science and TechnologyCollaborator
- Xianning Central HospitalCollaborator
- Xiamen UniversityCollaborator
- Hanyang UniversityCollaborator
- Wuhan UniversityCollaborator
- Shiyan Taihe HospitalCollaborator
- Wuhan UniversityCollaborator
- Xiang Yang NO.1 People's HospitalCollaborator
- Nanjing UniversityCollaborator
- People's Hospital Of YichangCollaborator
- Huangshi Central HospitalCollaborator
- Soochow UniversityCollaborator
- Huazhong University of Science and TechnologySponsor investigator
- Capital Medical UniversityCollaborator
- Nanyang Central HospitalCollaborator
- Enshi Tujia and Miao Autonomous Prefecture Central HospitalCollaborator
- Wuhan Puren HospitalCollaborator
- Zhengzhou UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.